Cleveland Clinic researchers are testing a novel immunotherapy/cancer vaccine combination in patients with recurrent glioblastoma, in hopes of finding an effective treatment for a condition with poor survival outcomes and a shortage of viable therapeutic options.
Cleveland Clinic Cancer Center physicians achieved remission in two patients with refractory advanced Merkel cell carcinoma by using a novel treatment that combines an immune checkpoint inhibitor and oncolytic viral immunotherapy.
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.